NOVO NORDISK A/S

NYSE: NVO (Novo Nordisk A/S)

最近更新时间: 22 Mar, 3:04PM

76.86

-1.93 (-2.45%)

  • 1天 -2.45%
  • 5天 -0.38%
  • 1月 -14.00%
  • 6月 -34.01%
  • 今年至今天 -12.18%
  • 1年 -39.22%
  • 5年 159.18%
前收盘价格 78.79
收盘价格 75.96
成交量 5,855,494
平均成交量 (3个月) 8,451,881
市值 341,641,166,848
市盈率 (P/E TTM) 23.22
预期市盈率 (P/E Forward) 19.01
价格/销量 (P/S) 8.08
股市价格/股市净资产 (P/B) 16.26
52周波幅
73.80 (-3%) — 148.15 (92%)
利润日期 7 May 2025
股息率 (DY TTM) 1.88%
营业毛利率 34.78%
营业利益率 (TTM) 49.69%
稀释每股收益 (EPS TTM) 3.31
季度收入增长率 (YOY) 30.10%
季度盈利增长率 (YOY) 28.50%
总债务/股东权益 (D/E MRQ) 71.64%
流动比率 (MRQ) 0.740
营业现金流 (OCF TTM) 120.97 B
杠杆自由现金流 (LFCF TTM) 61.99 B
资产报酬率 (ROA TTM) 22.41%
股东权益报酬率 (ROE TTM) 80.77%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 看涨
Drug Manufacturers - General (全球的) 看涨 看涨
股票 Novo Nordisk A/S 混合的 看涨

AIStockmoo 评分

0.3
分析师共识 1.5
内部交易活动 NA
价格波动 4.5
技术平均移动指标 -2.5
技术振荡指标 -2.5
平均 0.25

相关股票

股票 市值 DY P/E（TTM） P/B
NVO 342 B 1.88% 23.22 16.26
LLY 723 B 0.67% 68.94 52.04
MRK 225 B 3.50% 13.24 4.78
NVS 222 B 3.54% 19.18 4.89
JNJ 369 B 3.24% 26.47 5.50
ABBV 367 B 3.03% 87.24 109.22

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Growth
机构持股比例 10.25%

所有权

姓名 日期 持有股份
Everett Harris & Co /Ca/ 31 Dec 2024 6,453,089

该时间范围内无数据。

该时间范围内无数据。

  • 3M
日期 类型 细节
29 Mar 2025 公告 Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025
29 Mar 2025 CNBC Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years
29 Mar 2025 公告 Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025
27 Mar 2025 公告 Resolutions from the Annual General Meeting of Novo Nordisk A/S
24 Mar 2025 CNBC Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
24 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Mar 2025 公告 The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
24 Mar 2025 公告 Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
22 Mar 2025 CNBC Zepbound copycats remain online despite FDA ban
20 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
18 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
17 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
13 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action – Contact Lieff Cabraser
11 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Mar 2025 公告 Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
06 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
05 Mar 2025 CNBC Novo Nordisk offers Wegovy for less than half the price through new direct-to-consumer pharmacy
05 Mar 2025 公告 Novo Nordisk introduces NovoCare® Pharmacy, lowering cost of all doses of FDA-approved Wegovy® (semaglutide) to $499 per month and offering easy home delivery for cash-paying patients
05 Mar 2025 CNBC Amgen starts two critical late-stage trials for weight loss drug MariTide
04 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
03 Mar 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
27 Feb 2025 公告 Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S
27 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
26 Feb 2025 CNBC Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
25 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
24 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
21 Feb 2025 CNBC Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
20 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
18 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
13 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
11 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
10 Feb 2025 CNBC Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
07 Feb 2025 公告 Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children living with haemophilia A with and without inhibitors
06 Feb 2025 CNBC Eli Lilly to release late-stage data on next-generation weight loss drug retatrutide in 2025, earlier than expected
06 Feb 2025 公告 Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
06 Feb 2025 公告 Novo Nordisk A/S Investors: March 25, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser
05 Feb 2025 公告 Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
05 Feb 2025 公告 Novo Nordisk files annual report with the SEC
05 Feb 2025 CNBC Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
30 Jan 2025 公告 Lexaria Releases Annual Letter From the CEO
28 Jan 2025 CNBC Food-as-medicine startups hope Kennedy, if confirmed as HHS secretary, will boost their businesses
28 Jan 2025 CNBC FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
27 Jan 2025 公告 Novo Nordisk A/S - share repurchase programme
24 Jan 2025 公告 Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
17 Jan 2025 公告 Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
14 Jan 2025 CNBC Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
13 Jan 2025 CNBC Eli Lilly CEO expects new weight loss pill to be approved next year
13 Jan 2025 公告 Novo Nordisk A/S - share repurchase programme
13 Jan 2025 CNBC High cost of weight loss drugs drives employers to require nutrition counseling, in boost for startups
09 Jan 2025 CNBC Medicare can now cover Eli Lilly's Zepbound for sleep apnea, Health Department agency says
08 Jan 2025 公告 Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
显示更多
股息率 (DY TTM) 1.88%
5年平均股息收益率 2.48%
股息支付比率 43.78%
预计下次股息支付 Aug 2025
除息日 公告日期 支付日期 详情
31 Mar 2025 05 Feb 2025 08 Apr 2025 1.099206 现金
16 Aug 2024 06 Aug 2024 26 Aug 2024 0.5126402 现金
22 Mar 2024 31 Jan 2024 02 Apr 2024 0.92985 现金
18 Aug 2023 10 Aug 2023 29 Aug 2023 0.8835613 现金
24 Mar 2023 02 Feb 2023 04 Apr 2023 1.1887415 现金
12 Aug 2022 04 Aug 2022 23 Aug 2022 0.5835507 现金
25 Mar 2022 02 Mar 2022 05 Apr 2022 1.022423 现金
16 Aug 2021 - 25 Aug 2021 0.5502889 现金
26 Mar 2021 - 07 Apr 2021 0.922122 现金
14 Aug 2020 06 Aug 2020 25 Aug 2020 0.5177774 现金
27 Mar 2020 06 Feb 2020 07 Apr 2020 0.7826048 现金
16 Aug 2019 10 Aug 2019 27 Aug 2019 0.449438 现金
22 Mar 2019 05 Feb 2019 02 Apr 2019 0.777006 现金
17 Aug 2018 09 Aug 2018 28 Aug 2018 0.462327 现金
23 Mar 2018 24 Mar 2018 03 Apr 2018 0.805982 现金
17 Aug 2017 - 29 Aug 2017 0.33589 现金
23 Mar 2017 - 04 Apr 2017 0.479369 现金
11 Aug 2016 - 23 Aug 2016 0.331026 现金
18 Mar 2016 - 30 Mar 2016 0.69943 现金
19 Mar 2015 - 31 Mar 2015 0.532885 现金
21 Mar 2014 - 02 Apr 2014 0.606122 现金
21 Mar 2013 - 02 Apr 2013 2.264307 现金
22 Mar 2012 - 03 Apr 2012 1.831902 现金
24 Mar 2011 - 05 Apr 2011 1.357901 现金
25 Mar 2010 - 07 Apr 2010 0.978615 现金
19 Mar 2009 - 31 Mar 2009 0.781532 现金
13 Mar 2008 - 25 Mar 2008 0.678462 现金
08 Mar 2007 - 20 Mar 2007 0.891779 现金
09 Mar 2006 - 21 Mar 2006 0.691753 现金
10 Mar 2005 - 22 Mar 2005 0.61725 现金
17 Mar 2004 - 29 Mar 2004 0.52096 现金
26 Mar 2003 - 07 Apr 2003 0.37647 现金
13 Mar 2002 - 25 Mar 2002 0.2848 现金
21 Mar 2001 - 02 Apr 2001 0.5681 现金
24 Mar 2000 - 06 Apr 2000 0.4672 现金
25 Mar 1999 - 06 Apr 1999 0.4182 现金
27 Mar 1998 - 08 Apr 1998 0.3051 现金
25 Apr 1997 - 07 May 1997 0.239 现金
01 May 1996 - 14 May 1996 0.1806 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.10 1 1.43
2024 1.44 2 1.68
2023 2.07 2 2.00
2022 1.61 2 2.37
2021 1.47 2 2.63
2020 1.30 2 3.72
2019 1.23 2 4.24
2018 1.27 2 5.51
2017 0.815 2 3.04
2016 1.03 2 5.75
2015 0.533 1 1.84
2014 0.606 1 2.86
2013 2.26 1 12.26
2012 1.83 1 11.22
2011 1.36 1 11.78
2010 0.979 1 8.69
2009 0.782 1 12.24
2008 0.678 1 13.20
2007 0.892 1 13.75
2006 0.692 1 16.54
2005 0.617 1 21.94
2004 0.521 1 19.20
2003 0.376 1 18.38
2002 0.285 1 19.71
2001 0.568 1 28.33
2000 0.467 1 26.40
1999 0.418 1 32.36
1998 0.305 1 22.94
1997 0.239 1 16.57
1996 0.181 1 19.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票